Coherus BioSciences Culture Company

Dr. Alan C. Herman, Ph.D., has been the Chief Scientific Officer at Coherus Biosciences, Inc. since April 2011. Dr. Herman served as the Chief Scientific Officer and Vice President of Product Development of Althea Technologies Inc. He has over 30 years in the biopharmaceutical industry. He has been a pioneer in the biotechnology field beginning with Heptavax development while at Merck. From Merck, he moved to Genentech, where he was actively involved with the development of several early bio-tech products while in the Process Development Department and later, in Pharmaceutical R&D. He served as Director of Analytical Research and Development of Amgen. Following Amgen, he served as Senior Director of Quality Control at Tercica. He was the Founder of WindRose Analytica, Inc., a contract analytical laboratory specializing in protein analysis and characterization and served as its president. He has been involved in the establishment of the specified biologics concept since its inception and is often invited to speak on this and related topics at international meetings. He serves as a Member of Scientific Advisory Board at Althea Technologies, Inc. He received his B.S. and M.S. degrees in Biology at Indiana University of Pennsylvania. He received a Ph.D. in Protein Chemistry from Duke University and did his Post-Doctoral work in Oncogenic virus structure at Duke University Medical Center under Dr. Dani Bolognesi.

Dr. Peter Watler, Ph.D. has been the Chief Technical Officer of Coherus Biosciences Inc. since June 2014 and served as its Senior Vice President of Process Sciences since March 2012. Dr. Watler has over 25 years of biopharmaceutical process development and manufacturing experience, nearly half of which was gained in process development and manufacturing at Amgen. He is highly experienced with the development and scale-up of biopharmaceutical processes including key unit operations such as fermentation, centrifugation, filtration and chromatography. Dr. Watler has a strong skillset for process modeling, economic analysis, manufacturing operational excellence, process control and validation. His regulatory experience includes co-authoring two IND submissions, four BLA submissions and participation in several FDA inspections and GMP audits. He is a 12-year veteran of Amgen, which he joined in 1990. While at Amgen, Dr. Watler served roles leading process scale-up, manufacturing technical services and pilot plant operations. As Associate Director of Process Engineering, he oversaw the start-up of a 30,000 square foot pilot plant for monoclonal antibody development. In this role he implemented systems to accelerate technology transfer and scale up from the laboratory through to clinical production for over ten product candidates. He also led teams responsible for the process validation of Neupogen???, Stemgen???, Kepivance??? and Infergen???. Dr. Watler served as Chief Technology Officer of Hyde Engineering + Consulting, Inc. He led projects for GMP manufacturing facility design where he employed state-of-the-art technologies to drive down capital costs while enhancing cGMP compliance and operational efficiency. Dr. Watler has presented extensively in the US, Canada, China, Europe and Japan on the latest ICH, FDA and ASTM approaches to pharmaceutical risk management, process validation and Quality by Design. Dr. Watler was Vice President, Manufacturing at VaxGen. He led the design, construction and validation of a GMP facility for recombinant vaccine production. This fast-track project featured systems from top tier suppliers and went from design through construction to start-up in just 12 months. He was also responsible for managing supply chain and production operations, led the CMC team and prepared submissions for the FDA, NIH and DHHS. He began his career with Allelix Biopharmaceuticals as a Process Development Engineer optimizing fermentation mass transfer and product harvest operations. Dr. Watler holds a Bachelors and a Masters degree in Chemical Engineering from the University of Toronto where he developed a prototype implantable insulin pump and a Ph.D. in Chemical Engineering from Yamaguchi University, Japan where he implemented mechanistic modeling techniques for the scale-up and optimization of protein chromatography.

Dr. Barbara K. Finck, MD has been the Chief Medical Officer at Coherus Biosciences Inc. since July 2013 and served as its Senior Vice President of Inflammatory Diseases from July 2012 to July 2013. Dr. Finck served as the Chief Medical Officer of NKT Therapeutics, Inc. since October 2010. She served as Senior Vice President, Research & Development and Chief Medical Officer of Osprey Pharmaceuticals Ltd., since June 2007. Dr. Finck served as Senior Vice President and Chief Medical Officer of Osprey Pharmaceuticals U.S.A Inc. She served as a Vice President of Clinical Development at PDL BioPharma Inc. (formerly known as Protein Design Labs Inc.), since April 2003. She served as Vice President of Clinical Development at Eos Biotechnology Inc., from July 2001 to April 2003, when she commenced employment with Protein Design Labs Inc., following the acquisition of Eos by Protein Design Labs Inc. Prior to Eos, from July 1996 to July 2001, she served as a Medical Director of Immunex Corporation, where she was responsible for clinical development of the biopharmaceutical product Enbrelt for rheumatoid arthritis in adults and children. From October 1994 to July 1996, Dr. Finck served as a Clinical Program Manager and Medical Monitor of ALZA Corporation. From June 1992 to October 1994, Dr. Finck served as an Assistant Professor of Medicine at the University of California, San Francisco (UCSF). Previously, she served as a Member of the Scientific Advisory Board of the Association for Lupus Research. She is the co-author of numerous scientific publications appearing in Science, the New England Journal of Medicine and Lancet. She completed her residency in internal medicine and fellowship in rheumatology at the University of California, San Francisco. Dr. Finck holds a Bachelor's Degree in Physiological Psychology from the University of California, Santa Barbara, an MD from UCSF and is Board Certified in Internal Medicine and Rheumatology.

Mr. Vladimir Vexler, Ph.D has been Executive Vice President of Analytical and Translational Sciences at Coherus Biosciences, Inc. since April 25, 2017. Mr. Vexler served as Senior Vice President of Translational & Development Sciences at Coherus Biosciences, Inc. since June 7, 2016. Prior to joining Coherus in 2013, Mr. Vexler was a Senior Research Leader, Biotherapeutics at Hoffman-La Roche, where he acted as Global scientific leader for nonclinical safety of biotherapeutics and chaired Roche pRED Global Biotherapeutics Safety Team. Prior to that, Mr. Vexler was a Director of Translational Medicine at Facet Biotech and Protein Design Labs, where he established and led the Department of Translational Medicine and led biomarker support for several pre-IND and clinical programs including Zynbryta and Empliciti. From 1994 to 2004, he served in multiple positions in Pre-Clinical Development at Protein Design Labs. Mr. Vexler began his career as a post-doctoral fellow at the Department of Radiology at UCSF. Mr. Vexler has several peer-review publications in mAb development for immune-mediated inflammatory diseases and cancer. He earned a Ph.D. in Biology from the Institute of Chemical Physics, Academy of Science in Moscow and a M.S., Chemistry/Enzymology from the Moscow State University.

Mr. Matthew R. Hooper, also known as Matt, has been General Counsel of Coherus Biosciences, Inc. since September 2013 and its Executive Vice President since June 7, 2016. Mr. Hooper joined Coherus in October 2012 as Vice President, Legal Affairs. He served as Senior Vice President of Coherus Biosciences, Inc. since September 2013 until June 7, 2016. Before joining Coherus, Mr. Hooper was Of Counsel with the Life Sciences Group of Wood, Phillips, Katz, Clark and Mortimer in Chicago, where Coherus was one of his principal clients. Mr. Hooper served as the General Counsel and Vice President of Halozyme Therapeutics, Inc. from November 13, 2007 to July 2008. Mr. Hooper has over 25 years of legal experience. Most recently, he served as an Assistant General Counsel of Johnson & Johnson (J&J), where he served in a dual role as member of J&J's Law Department, and Vice-President of Law for Scios, Inc., a wholly-owned J&J subsidiary focused on cardiovascular therapeutics, from 2005 to 2006. He served as General Counsel and Vice President of Scios Inc. since October 2001 and served as its Secretary. From 2003 to 2005, Mr. Hooper served as Senior Counsel at J&J, where he handled all commercial legal affairs related to Scios' integration into J&J following completion of the $2.5 billion merger in April 2003. From October 2001 to 2003, he served as Vice President and General Counsel of Scios, where he oversaw all legal aspects and its operations. He joined Scios in 2000 as Senior Patent Counsel, with responsibility for all intellectual property matters for Scios. From 1999 to 2000, Mr. Hooper was Senior Counsel in the litigation group of Jones Day Reavis and Pogue in Chicago. From 1994 to 1999, he held the position of Patent Counsel of Abbott Laboratories in its patent and trademark department, where he was responsible for U.S. and foreign patent preparation and prosecution, litigation support, legal opinions and contract preparation supporting Abbott's diagnostics businesses. Before joining Abbott, he served as a patent attorney at Amoco Corporation from 1985 to 1994, and was an associate attorney in private practice in Chicago from 1982 to 1985. Mr. Hooper received his JD degree from Northwestern University Law School and his BS degree in Chemistry from LaSalle University.

Dr. Carl Ware, Ph.D. is a Director and Professor at the Infectious and Inflammatory Disease Center at the Sanford-Burnham Medical Research Institute. Dr. Ware is a leading immunologist and virologist internationally recognized for his scientific discoveries and advances in the study of the immune system that are leading to new therapeutics for autoimmune and viral diseases and cancer. In 1981, Dr. Ware joined the research groups of Dr. Jack Strominger and Dr. Tim Springer at Dana-Farber Cancer Institute, Harvard Medical School. Dr. Ware established his own research laboratory in 1982 as an assistant professor of Immunology in the Biomedical Sciences Program at the University of California, Riverside, advancing to full professor in 1993. In 1996, Dr. Ware joined the prestigious La Jolla Institute for Allergy and Immunology as head of the Division of Molecular Immunology. Dr. Ware holds a joint appointment as professor in the Department of Biology at the University of California, San Diego. In 2010, Dr. Ware was recruited to the Sanford Burnham Medical Research Institute in La Jolla as director of the Infectious and Inflammatory Diseases Center. Dr. Ware serves as a Member of Scientific Advisory Board at Coherus Biosciences, Inc. From 1979 to 1981, Dr. Ware studied membrane biochemistry and the complement system with Dr. W. Kolb at the University of Texas Health Science Center in San Antonio. He received his Ph.D. in Molecular Biology and Biochemistry in 1979 from University of California, Irvine.

Vince Anicetti serves as the Chief Operations Officer for Coherus BioSciences. Vince started at Coherus BioSciences in April of 2018. Vince is based in the San Francisco Bay Area.

Henriette Kuehne serves as the Executive Director, Analytical & Pharmaceutical Sciences for Coherus BioSciences. Henriette started at Coherus BioSciences in June of 2016. Henriette is based in the Greater Los Angeles Area.

Christopher Colburn serves as the Executive Director, Payers & Trade for Coherus BioSciences. Christopher started at Coherus BioSciences in April of 2018. Christopher is based in the Greater Philadelphia Area.